Comparative Pharmacology
Head-to-head clinical analysis: ALDACTONE versus AMILORIDE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDACTONE versus AMILORIDE HYDROCHLORIDE.
ALDACTONE vs AMILORIDE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive aldosterone receptor antagonist; increases sodium and water excretion, decreases potassium excretion at distal convoluted tubule.
Amiloride hydrochloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct of the nephron, inhibiting sodium reabsorption and reducing potassium and hydrogen ion secretion.
Initial: 50-100 mg orally once daily; may increase to 100-400 mg/day in divided doses (once to twice daily).
5-10 mg orally once daily; maximum 20 mg/day.
None Documented
None Documented
Spironolactone: 1.4-2.0 hours; Active metabolites (canrenone): 16.5-21.5 hours, clinically relevant for dosing interval
Terminal elimination half-life is 6-9 hours; prolonged to 20-24 hours in renal impairment
Renal: 50-60% as metabolites (canrenone, other sulfur-containing metabolites), minor as unchanged drug; Biliary/Fecal: ~30-40%
Renal, approximately 50% unchanged; minor biliary/fecal elimination (<10%)
Category C
Category C
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic